Characterization of indeterminate renal masses with molecular imaging: how do we turn potential into reality?

Steven P. Rowe 1*, Mehrbod S. Javadi 1, Mohamad E. Allaf 2 and Michael A. Gorin 2

Keywords: Small renal mass, Renal cell carcinoma, Oncocytoma, SPECT/CT, 99mTc-sestamibi

Background
The majority of enhancing renal masses are unable to be effectively characterized as benign or malignant using standard cross-sectional imaging modalities including multi-phase computed tomography (CT) [1] and magnetic resonance imaging (MRI) [2]. This is particularly unfortunate in light of the steady increase in the incidence of these lesions, many of which are discovered incidentally on imaging studies performed for non-urologic indications [3, 4]. Moreover, it has been estimated that upwards of 5600 unnecessary partial and radical nephrectomies are performed each year in the USA for the false presumption of cancer [5]. In light of these data, recently, there has been a growing interest in the use of molecular imaging to characterize the aggressiveness of renal masses [6, 7].

To date, several reports have been published on the ability of 99mTc-sestamibi planar and single photon emission computed tomography (SPECT)/CT imaging to differentiate mitochondrial-rich benign and indolent renal masses such as oncocytomas and hybrid oncocytic/chromophobe tumors (HOCTs) from more aggressive renal tumor histologies including the clear cell subtype of renal cell carcinoma (RCC) [8–10]. In this issue of European Journal of Nuclear Medicine and Molecular Imaging Research, Tzortzakakis et al. [11] add to this body of literature with a prospective study evaluating 99mTc-sestamibi SPECT/CT in 24 patients with 31 clinically localized T1 renal masses planned for biopsy or surgery. The authors reported that 11 of 12 (92%) oncocytomas and 3 of 3 (100%) HOCTs demonstrated 99mTc-sestamibi uptake, while all other lesions were negative for uptake with the exception of mild uptake in a single papillary RCC. These findings are concordant with earlier studies [9, 10] and dramatically increase the number of 99mTc-sestamibi positive oncocytomas and HOCTs reported in the literature.

As a brief aside, it should be mentioned that there is also a growing interest in the use of renal mass biopsy for determining the histology of renal tumors, particularly as data from two recent systematic reviews have suggested that the rates of complications and non-diagnostic biopsies are tolerable [12, 13]. However, limitations of renal mass biopsy remain, including the intrinsically invasive nature of this procedure, the inaccessibility of some tumors to safe approaches for biopsy, and the heterogeneous population of renal masses that can present as oncocytic neoplasms on biopsy [14, 15]. As such, the non-invasive characterization of renal masses with molecular imaging techniques continues to be of interest and may serve as an adjunct to, or even a replacement of, biopsy in selected cases.

Additional prospective studies
The MIDOR (Molecular Imaging for Differential Diagnosis of Oncocytoma from Renal Cell Carcinoma) Trial, from which the manuscript by Tzortzakakis et al. [11] reports initial results, is the first report in the literature on the implementation of 99mTc-sestamibi SPECT/CT outside of Johns Hopkins Hospital in Baltimore, MD, USA. Additional prospectively collected data are critical for validating the robustness of this imaging test across centers, scanners, and interpreting imaging experts.
 Ultimately, we can expect that the pearls and pitfalls of using 99mTc-sestambib SPECT/CT for renal mass characterization will become most apparent with increased patient numbers. Additionally, larger datasets are required to ensure that all renal tumor histologies (some of which are quite rare) are studied in sufficient numbers to establish the various patterns of 99mTc-sestambib uptake.

**Development of improved quantitative methods**

SPECT imaging has long been considered a qualitative modality; however, new methods for attenuation correction, scatter correction, compensation for distance-dependent blurring/collimator-detector response, and partial volume correction have allowed for true quantitative SPECT to be performed [16]. While both Rowe et al. [9] and Gorin et al. [10] utilized a semi-quantitative method to describe the uptake of 99mTc-sestambib by renal masses, the method used in these reports (ratio of the highest count voxel in the mass to the highest count voxel in the ipsilateral renal parenchyma) is subject to potential error. Moreover, the images that were used for this analysis were from standard clinical non-quantitative acquisitions.

As Tzortzakakis et al. [11] astutely point out in the “Discussion” section of their manuscript that quantitative methods may be of importance for optimal characterization of renal masses with 99mTc-sestambib SPECT/CT. Although a visual analysis of renal masses imaged with 99mTc-sestambib SPECT/CT will always be an important part of interpreting these studies, a numerical threshold (as has been proposed by Gorin et al. [10]) may be a useful interpretational adjunct. However, determination of true SPECT standardized uptake values is likely to be a more reliable means of characterizing these tumors. Thus, further investigation of quantitative SPECT methodologies is needed.

**Pipeline of new radiotracers**

The promise of 99mTc-sestambib SPECT/CT must be tempered by the fact that an imaging test that uses a single radiotracer can provide only limited information for characterizing indeterminate renal masses. Indeed, while 99mTc-sestambib uptake appears to allow for the reliable identification of benign/indolent oncocytomas and HOCTs [9–11], not all masses that fail to accumulate 99mTc-sestambib will behave in an aggressive manner (e.g., chromophobe RCC and low-grade papillary RCCs). As such, the use of other radiotracers in addition to 99mTc-sestambib may allow for more complete risk stratification. Already, the radiolabeled monoclonal antibody 124I-girentuximab has been used in a phase III clinical trial to identify clear cell RCCs using positron emission tomography (PET) imaging through binding to carbonic anhydrase IX (CAIX), a cell surface enzyme that is not expressed in normal renal tissue or by other renal tumor histologies [17]. New small molecule SPECT and PET radiotracers that target carbonic anhydrase IX are in preclinical development (for example [18] and [19]). The SPECT agent described in Yang et al. [18] is of particular interest given its labeling with 111In which would allow for dual radiotracer SPECT in combination with 99mTc-sestambib.

Although lacking dual radiotracer capability, PET does have advantages over SPECT including established methods of quantitation and superior spatial resolution. As such, the development of PET radiotracers for renal mass characterization should be of significant interest to the field. As noted above, a CAIX PET radiotracer (124I-girentuximab) has already been extensively studied and may prove clinically useful in the future [17]. Furthermore, mitochondrial PET imaging agents have been described for cardiac and non-cardiac applications [20, 21] and deserve to be explored for their potential utility in identifying mitochondrial-rich renal masses such as oncocytomas and HOCTs.

**Conclusions**

The work of Tzortzakakis and coworkers [11] is a critical step in laying the foundation for the widespread use of molecular imaging for renal mass characterization, although further efforts would be of value for advancing the field to the point of routine clinical application. Additional prospectively collected data as well as research in quantitative imaging methods and the development of novel radiotracers could usher in an era of non-invasive renal mass characterization. The refinement of molecular imaging techniques for renal mass characterization should be a priority for nuclear medicine, as this has the potential to greatly benefit patients by sparing many of the morbidity of invasive procedures in addition to unnecessary renal surgery.

**Abbreviations**

CAIX: Carbonic anhydrase IX; CT: Computed tomography; HOCT: Hybrid oncocytoma/chromophobe tumor; MIDOR: Molecular Imaging for Differential Diagnosis of Oncocytoma from Renal Cell Carcinoma; MRI: Magnetic resonance imaging; PET: Positrion emission tomography; RCC: Renal cell carcinoma; SPECT: Single photon emission computed tomography

**Authors’ contributions**

All authors contributed to the conceptualizing and drafting of the manuscript. All authors read and approved the final manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Author details
1Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 600 N. Wolfe St., Baltimore, MD 21287, USA. 2The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Received: 14 March 2017 Accepted: 15 March 2017

References
1. Pierorazio PM, Hyams ES, Tsai S, et al. Multiphasic enhancement patterns of small renal masses (≤ 4 cm) on preoperative computed tomography: utility for distinguishing subtypes of renal cell carcinoma, angiomyolipoma, and oncocytoma. Urolgy. 2013;81:1265–71.
2. Pedrosa I, Sun MR, Spencer M, et al. MR imaging of renal masses: correlation with findings at surgery and pathologic analysis. Radiographics. 2008;28:985–1003.
3. Gill IS, Aron M, Gervais DA, Jewett MA. Clinical practice. Small renal mass. N Engl J Med. 2010;362:624–34.
4. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98:1331–4.
5. Johnson DC, Vukina J, Smith AB, et al. Preoperatively misclassified, surgically removed benign renal masses: a systematic review of surgical series and United States population level burden estimate. J Urol. 2015;193:30–5.
6. Gorin MA, Rowe SP, Allaf ME. Nuclear imaging of renal tumours: a step towards improved risk stratification. Nat Rev Urol. 2015;12:445–50.
7. Gorin MA, Rowe SP, Allaf ME. Noninvasive determination of renal tumor histology utilizing molecular imaging. Urol Oncol. 2016;34:425–8.
8. Gormley TS, Van Every MJ, Moreno AJ. Renal oncocytoma: preoperative diagnosis using technetium 99 m sestamibi imaging. Urolgy. 1996;48:33–9.
9. Rowe SP, Gorin MA, Gerdetskiy J, et al. Initial experience using 99mTc-MIBI SPECT/CT for the differentiation of oncocytoma from renal cell carcinoma. Clin Nucl Med. 2015;40:309–13.
10. Gorin MA, Rowe SP, Baras AS, et al. Prospective evaluation of (99m)Tc-sestamibi SPECT/CT for the diagnosis of renal oncocytomas and hybrid oncocytic/chromophobe tumors. Eur Urol. 2016;69:413–6.
11. Tzortzakakis A, Gustafsson O, Karlsson M, Ekstrom-Ehn L, Ghaffarpour R, Axelsson R. Visual evaluation and differentiation of renal oncocytomas from renal cell carcinomas by means of 99mTc-sestamibi SPECT/CT. EJNMMI Res. 2017;7:29.
12. Marconi L, Dabestani S, Lam TB, et al. Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol. 2016;69:660–73.
13. Patel HD, Johnson MH, Pierorazio PM, et al. Diagnostic accuracy and risks of biopsy in the diagnosis of a renal mass suspicious for localized renal cell carcinoma: systematic review of the literature. J Urol. 2016;195:1340–7.
14. Gorin MA, Rowe SP, Allaf ME. Oncocytic neoplasm on renal mass biopsy: a diagnostic conundrum. Oncology (Williston Park). 2016;30:426–35.
15. Patel HD, Druskin SC, Rowe SP, Pierorazio PM, Gorin MA, Allaf ME. Surgical histopathology for suspected oncocytoma on renal mass biopsy: a systematic review and meta-analysis. BJU Int. 2017, in press.
16. Bailey DL, Willowson KP. An evidence-based review of quantitative SPECT imaging and potential clinical applications. J Nucl Med. 2013;54:83–9.
17. Divgi CR, Uzzo RG, Gatoonis C, et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol. 2013;31:187–94.
18. Yang X, Minn I, Rowe SP, et al. Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor. Oncotarget. 2015;6:33733–42.
19. Minn I, Koo SM, Lee HS, et al. [64Cu]Y1MSR-06: a dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma. Oncotarget. 2016;7:56471–9.
20. Berman DS, Maddahi J, Tamarapoo BK, et al. Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography. J Am Coll Cardiol. 2013;61:469–77.